Biogen climbs as profits surge 72%, prompting the firm to boost 2019 guidance

  • Biogen jumped about 2% in early trading on Tuesday after beating estimates and raising guidance for the rest of 2019.
  • The company’s multiple sclerosis therapy led the company’s 72% revenue growth in the second quarter. The treatment brought in $US100 million more than analysts’ consensus estimate.
  • The earnings beat comes as shares are down about 35% over the last 12 months. Biogen plummeted on March 21 after it announced its Alzheimer drug would be discontinued after failing late-stage trials.
  • Watch Biogen trade live here.

Biogen shares rose roughly 2% in early trading after the company beat second-quarter estimates and raised its guidance for the rest of 2019.

The company’s improved outlook follows a 72% quarterly profit jump, led by its multiple sclerosis therapy product. The therapy, Tecfidera, brought in $US1.15 billion in sales, beating the $US1.05 billion estimate.

The Tuesday morning report also announced adjusted earnings per share of $US9.15, blowing past Wall Street’s $US7.53 estimate.

The positive news follows a drop of about 35% in the shares’ value over the last 12 months, representing a loss of about $US30 billion in market cap. Biogen shares fell more than 29% on March 21 after the company announced its Alzheimer drug failed late-stage trials and would be discontinued.

Markets Insider is looking for a panel of millennial investors. If you’re active in the markets, CLICK HERE to sign up.

Biogen said it expects yearly revenue to land between $US14 billion and $US14.2 billion, up from previous estimates ranging from $US13.6 billion to $US13.8 billion.

Biogen shares closed at $US232.48 Monday. The company has 6 “buy” ratings, 25 “hold” ratings, and 2 “sell” ratings from analysts and a 12-month price target of $US254.52 per share, according to Bloomberg data.

Now read more markets coverage from Markets Insider and Business Insider:

Carl Icahn criticises petroleum giant Occidental’s recent mega-merger, says Warren Buffett took its CEO ‘to the cleaners’

Disney stock jumps after ‘The Lion King’ and ‘Avengers: Endgame’ set box office records

VCs say these 7 space tech firms are set to crush the market in the $US350 billion race for space

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.